We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

121 hedge funds and large institutions have $316M invested in Rigel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more call options, than puts

Call options by funds: $3.05M | Put options by funds: $1.07M

69% more capital invested

Capital invested by funds: $187M → $316M (+$129M)

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

2% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 42

1% more funds holding

Funds holding: 120 → 121 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
121
Holders Change
+1
Holders Change %
+0.83%
% of All Funds
3.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
43
Reduced
42
Closed
18
Calls
$3.05M
Puts
$1.07M
Net Calls
+$1.99M
Net Calls Change
+$1.7M

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$6.86M
2
Goldman Sachs
Goldman Sachs
New York
+$4.75M
3
CAM
Cormorant Asset Management
Massachusetts
+$3.31M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.19M
5
CS
Candriam SCA
Luxembourg
+$2.08M

Top Sellers

1
DM
Deerfield Management
New York
-$5.2M
2
DCM
DAFNA Capital Management
California
-$4.32M
3
ACP
Acuta Capital Partners
California
-$2.14M
4
NI
Numeric Investors
Massachusetts
-$1.89M
5
SAM
Senzar Asset Management
New York
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$52M +$1.03M +35,949 +3%
PAI
2
Palo Alto Investors
California
$19M -$575K -20,044 -4%
O
3
OppenheimerFunds
New York
$18.4M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$17.8M +$675K +23,529 +5%
Wellington Management Group
5
Wellington Management Group
Massachusetts
$17.7M -$854K -29,783 -6%
BFA
6
BlackRock Fund Advisors
California
$14.1M +$751K +26,195 +7%
Citadel Advisors
7
Citadel Advisors
Florida
$12.9M +$6.86M +239,325 +215%
BIT
8
BlackRock Institutional Trust
California
$12M +$94.2K +3,285 +1%
NMC
9
NEA Management Company
Maryland
$11.9M – – –
JP Morgan Chase
10
JP Morgan Chase
New York
$7.94M +$1.64M +57,352 +36%
Millennium Management
11
Millennium Management
New York
$7.72M -$749K -26,143 -11%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$7.05M -$1.43M -49,836 -21%
RSCM
13
Rock Springs Capital Management
Maryland
$6.64M +$172K +6,000 +3%
Goldman Sachs
14
Goldman Sachs
New York
$6.49M +$4.75M +165,785 +1,504%
State Street
15
State Street
Massachusetts
$5.87M +$30.6K +1,067 +0.7%
Dimensional Fund Advisors
16
Dimensional Fund Advisors
Texas
$5.26M -$62.9K -2,193 -2%
RPAM
17
Rhenman & Partners Asset Management
Sweden
$5.14M +$1.58M +55,000 +65%
BC
18
Boxer Capital
California
$4.96M +$1.87M +65,114 +93%
CAM
19
Cormorant Asset Management
Massachusetts
$4.24M +$3.31M +115,560 New
Northern Trust
20
Northern Trust
Illinois
$3.79M +$33.8K +1,180 +1%
SCM
21
Sio Capital Management
New York
$3.75M -$897K -31,298 -23%
T. Rowe Price Associates
22
T. Rowe Price Associates
Maryland
$3.58M +$2.19M +76,401 +363%
SAM
23
Senzar Asset Management
New York
$3.33M -$1.54M -53,580 -37%
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$3.23M – – –
State of New Jersey Common Pension Fund D
25
State of New Jersey Common Pension Fund D
New Jersey
$3.12M +$860K +30,000 +55%
1
2 3 4 5

RIGL Hedge Fund Activity: Q3 2016 in Review

121 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2016, worth a combined $316M — up 69% from $187M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RIGL positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 42 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $6.86M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.2M sold.

  • 121 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2016, up from 120 in Q2 2016.
  • Funds reported $316M of Rigel Pharmaceuticals stock for Q3 2016, up 69% quarter-over-quarter.
  • 19 funds opened new Rigel Pharmaceuticals positions in Q3 2016 and 18 closed out, a net change of +1 holder.
  • The largest Rigel Pharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $6.86M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2016 was Deerfield Management, an estimated $5.2M sold.

Based on aggregated 13F filings for Q3 2016.